Oncology Institute, Inc. ( (TOI) ) has released its Q3 earnings. Here is a breakdown of the information Oncology Institute, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The Oncology Institute, Inc. (NASDAQ: TOI) is a leading value-based community oncology group in the United States, providing specialized cancer care through a network of clinics and affiliate locations across multiple states. In its third quarter of 2025, the company reported a significant increase in consolidated revenue, reaching $136.6 million, a 36.7% rise compared to the same period in 2024. This growth was driven by a 13% increase in fee-for-service revenue and record-setting performance in its retail pharmacy and dispensary sectors.
Key financial metrics for the quarter included a gross profit of $18.9 million, marking a 31.7% increase, and a net loss of $16.5 million, slightly higher than the previous year’s loss of $16.1 million. The company also reported an improvement in adjusted EBITDA, which was $(3.5) million compared to $(8.2) million in the prior year. The Oncology Institute’s cash and cash equivalents stood at $27.7 million as of September 30, 2025.
Strategically, the company expanded its network by signing new in-network MSO providers in Florida and opening a new pharmacy location in the state. Additionally, the appointment of Kristin England as Chief Administrative Officer is expected to enhance the company’s operational efficiency and technology strategy.
Looking ahead, The Oncology Institute has updated its full-year 2025 guidance, projecting revenue between $495 to $505 million and maintaining its gross profit forecast. The company anticipates adjusted EBITDA to be in the range of $(11) to $(13) million, reflecting its confidence in continued growth and operational improvements. Despite the challenges, the company remains committed to advancing value-based oncology care while driving sustainable growth.